

**Tobacco, diabetes, HIV, and
Tuberculosis: The importance of
dynamic modeling when chronic and
infectious diseases interact**

Kristen Hassmiller Lich, klich@unc.edu

23 June 2009

Department of Health Policy and Administration

School of Public Health

University of North Carolina at Chapel Hill

This work is supported in part by a grant from the University of Michigan Tobacco Research Network and the American Legacy Foundation

Overview

- Tuberculosis control policy context
- Key risk factors
- TB and tobacco -- illustrating approach and lessons learned
- TB and diabetes -- work in progress

Tuberculosis (TB)

- TB is an airborne communicable disease
- TB is a leading cause of death worldwide
- 1/3 of the world's population is infected
- 10-15% of those infected will progress to disease in their lifetime
- Inexpensive and effective treatment available

Traditional TB control

- “Prevention starts with cure”
- Five core principles of DOTS
 - Clear and sustained political commitment
 - **Accurate case detection** through quality assured technology
 - **Standardized treatment** including patient support and supervision
 - Reliable and effective drug supply
 - Capable monitoring and evaluation system

Global TB goals

- Millennium Development Goals
 - To reverse the increasing trend in TB incidence rates
 - To halve TB prevalence and death rates between 1990 and 2015
- Process goals
 - To diagnose 70% of new TB cases
 - To successfully treat 85% of these

Global TB Control

- Stop TB Strategy (2006)
 - Continue DOTS expansion
 - Address drug resistance
 - Address TB-HIV coinfection
 - Strengthen health systems
 - Engage all health care providers in TB control (public and private)
 - Enable and encourage research to advance TB diagnosis, treatment, and prevention

Current policy issues

- In 2007 an estimated 94% of people lived in areas covered by DOTS programs
- Many countries have reached (or are close to reaching) treatment targets
 - But many are NOT on track for meeting corresponding outcome goals
 - WHY?
- New policy focus emerging: TB elimination
 - Reduce TB incidence rate to 1/100,000 in the next 50 years
 - HOW?

Key TB Risk Factors

- On the “policy radar screen”
 - HIV infection
- Missing
 - Diabetes
 - Tobacco exposure (active and SHS)
 - Malnutrition
 - Alcohol or drug abuse
 - Indoor air pollution
 - Spending time in a prison, a health care setting, a country with high TB prevalence
 - (MANY OTHERS!)

Big picture questions...

- Why aren't we seeing projected decreases in TB incidence rates -- **what's missing from our model?**
- **What are feasible TB control options** including, but looking beyond, pharmacological solutions? What are the constraints to which each might work in particular environments? Consider targeted use...
- Recognizing that resources are limited and given that what is feasible and sustainable in one community may not be in another -- **what should TB control look like (and how does "where" affect this answer)?**
- What will happen to TB outcomes if one of these **missing risk factors becomes more prevalent?**
- What would it take to get us to **TB elimination** targets?

Research questions...

- Which risk factors are most important?
- We must care about this...
 - Because we can't do everything
 - To motivate the general population (or providers, or funders, etc)

The association between smoking and TB

Relative risk for ever versus never-smokers:	
Being infected	1.7 (1.3-2.0)
Developing TB disease	2.7 (2.0-3.9)
Dying from TB	2.4 (1.3-4.2)
Relative risk for smokers compared to non-smokers:	
Treatment default	2.0 (1.5-2.5)
Smear conversion	0.6 (0.4-0.8)
Cavitary TB	1.9 (1.6-2.2)

Impact assessment

Population Attributable Risk % (PAR%)

$$\begin{aligned} \text{PAR}\% &= \frac{p^*(\text{RR}-1)}{p^*\text{RR}+(1-p)^*1} * 100 \\ &= \frac{p^*(\text{RR}-1)}{p^*(\text{RR}-1)+1} * 100 \end{aligned}$$

where p=prevalence of exposure;
RR=Relative Risk

Impact assessment

	RR	PAR%*
Developing TB	2.7	34%
Dying of TB	2.4	29%

* 29% ever-smoking prevalence

(Source: Mackay, Eriksen, Shafey 2006. *The Tobacco Atlas*, 2nd edition.)

Impact assessment

	RR	PAR%*	Model estimate*
Developing TB (Uncertainty in mechanisms) (Uncertainty in TB parameters)	2.7	34%	60% (59-72%) (56-65%)
Dying from TB (Uncertainty in mechanisms) (Uncertainty in TB parameters)	2.4	29%	57% (55-69%) (52-62%)

* 29% ever-smoking prevalence

(Source: Mackay, Eriksen, Shafey 2006. *The Tobacco Atlas*, 2nd edition.)

Impact of smoking, by smoking status

	Overall*	Ever-smokers*	Never-smokers*
Developing TB (Uncertainty in mechanisms) (Uncertainty in TB params.)	60% (59-72%) (56-65%)	78% (78-84%) (75-81%)	42% (39-59%) (36-48%)
Dying from TB (Uncertainty in mechanisms) (Uncertainty in TB params.)	57% (55-69%) (52-62%)	74% (74-83%) (71-78%)	42% (38-58%) (36-48%)

* 29% ever-smoking prevalence

(Source: Mackay, Eriksen, Shafey 2006. *The Tobacco Atlas*,
2nd edition.)


Research questions (cont)...

- How specifically does each risk factor affect TB dynamics?
- We must care about this...
 - To get the model right
 - To accurately prioritize leverage points
 - To inspire innovative thoughts about intervention

Effects of tobacco exposure on TB dynamics

- Smoking:
 - causes structural changes in the respiratory tract
 - impairs immune response
 - increases risk of transmission
 - alters treatment rate
 - increases non-TB death rate
 - is social

Effects of tobacco exposure on TB dynamics -- and interventions



Smoking is a modifiable risk factor...

- Potential tobacco control policies: taxation, education, warning labels, restrictions on supply, ad bans, smoking bans in public places
- We can:
 - Prevent initiation
 - Encourage cessation
 - Support cessation
 - Encourage harm reduction strategies

Smoking is an identifiable risk factor...

- Encourage PAL approach
- Screen smokers for TB infection and disease
- Use chemoprophylaxis among recently infected smokers
- Intensify measures to make sure smokers comply with TB treatment

Policy modeling: India

Case study: India

- Substantial TB epidemic
 - >20% of new TB cases globally
- Close to reaching treatment targets
- No evidence of meeting corresponding outcome targets
- <5% of TB cases co-infected with HIV, 0.5% of population HIV+ overall

Tobacco use in India

- Average age of initiation 20-25
- Adult smoking prevalence (25+)
 - 38% among men
 - 3% among women
- Focus on smoked tobacco, though smokeless tobacco widely used
- May be on the rise (need more data)


Tobacco control in India

- In 2003, established comprehensive tobacco-control policy
 - Increased tobacco taxation
 - Restrictions on smoking in public places
 - Advertising ban
- Need to strengthen existing policies, and add
 - Information/counter-advertising
 - Support for successful cessation
- GOAL: to reduce smoking prevalence by 15-25% by 2020


So...

- What will happen if tobacco-control policy is not enhanced (and smoking prevalence increases)?
- What will happen to population-level TB outcomes if tobacco-control targets are met?


Policy implications: India




Policy implications: India




Policy implications: India




Policy implications: India




Policy implications: India



Policy implications: India



Policy implications: India



Diabetes and TB...

The association between diabetes and TB

- Less is known...
- Diabetes is associated with risk of developing TB disease (estimated odds ratios range from 1.15 to 8)
- Limited evidence suggests immune effects at play
- Diabetics who develop pulmonary TB are more likely to develop smear-positive and cavitory disease
- Diabetics are sometimes more likely to default from treatment programs
- Diabetics on TB treatment are less likely to experience smear conversion within 2 months of treatment
- Diabetics with TB may be more likely to die

» (Source: Stevenson et al (2007) in Chronic Illness 3:228)

Diabetes and TB

- Evidence is more varied than for tobacco exposure
- Less evidence about causality (more of a puzzle remains)
- How much of the increased risk is driven by late-stage diabetes?
- What specific mechanisms are at play?

Work in progress in Saskatchewan...

- Objectives...
 - To learn more about mechanisms and the magnitude of TB effects
 - To learn more about interactions between risk factors
 - To identify powerful, feasible, and locally-tailored intervention packages
 - To begin to understand how power of policies varies by environment

Why build simulation models?

- Systems are complex
- Make *mental models* explicit, develop shared understanding
- Virtual world in which to test and compare intervention strategies at population level and **identify key leverage points**
- Tool for engaging stakeholders and policy makers to identify the most cost effective and locally acceptable interventions (**foundation for discussing trade-offs**)
- Help **identify most important gaps** in our understanding of the system

Thank you!

(Feel free to email:
klich@unc.edu)